Lupus Science & Medicine
Figure 1 Proportions of patients attaining (A) DORIS remission, (B) LLDAS and (C) LLDAS-5 over 52 weeks. DORIS remission, LLDAS and LLDAS-5 response rates and nominal p values were calculated using a stratified Cochran–Mantel–Haenszel approach, with stratification factors SLEDAI-2K score at screening, Day 1 GC dose, type I IFNGS test result at screening and study (TULIP-1 vs TULIP-2). Nominal p values for anifrolumab 300 mg versus placebo in IS-inexperienced patients: *p < 0.05; **p < 0.01; ***p < 0.001. Nominal p values for anifrolumab 300 mg versus placebo in IS-experienced patients: ˆp < 0.05; ˆˆp < 0.01; ˆˆˆp < 0.001. DORIS, Definition of Remission in SLE; GC, glucocorticoid; IFNGS, type I interferon gene signature; IS, immunosuppressant; LLDAS, Lupus Low Disease Activity State; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.
6
Doria A, et al . Lupus Science & Medicine 2026; 13 :e001891. doi:10.1136/lupus-2025-001891
Powered by FlippingBook